{"metadata":{"topics":["Accountability","Accounting","Administrative law","Annexation","Applied ethics","Arbitration","Artificial objects","Asset","Audit","Breakup fee","Budget","Business","Business economics","Business law","Business organizations","Canada","Capital (economics)","Change","Civil law (common law)","Civil law (legal system)","Civil rights and liberties","Cognition","Cognitive science","Committee","Common law","Communication","Companies","Comparative law","Confidentiality","Constitutional law","Contract","Contract law","Corporate finance","Corporate governance","Corporate jargon","Corporate law","Corporate personhood","Corporate tax","Corporation","Corporations","Cost","Court","Credit","Crime","Criminal justice","Criminal law","Culture","Data","Decision-making","Definition","Diligence","Discovery (law)","Doctrines","Documents","Drug","Drug delivery","Due diligence","Economic law","Economic sectors","Economics","Economies","Economy","Economy of the United States","Email","Emergence","England","English law","Environmental law","Epistemology","Ethical principles","Ethically disputed business practices","Europe","Expense","Experience","Expert","Expert witness","Externality","Family economics","Fee","Finance","Financial accounting","Financial economics","Financial law","Financial markets","Financial services","Food and Drug Administration","Good faith","Government","Government agencies","Government and personhood","Government finances","Government information","Government institutions","Government of South Africa","Government of the United States","Human activities","Human communication","Human rights","Income","Indemnity","Industries","Industry","Information","Information science","Intellectual property law","Intellectual works","International law","International relations","Investment","Investor","Israel","Jargon","Judiciaries","Jurisprudence","Justice","Justification","Know-how","Law","Law and economics","Law of obligations","Leadership","Legal communication","Legal concepts","Legal doctrines and principles","Legal documents","Legal ethics","Legal fictions","Legal literature","Legal procedure","Legal writing","License","London","Love","Management","Manufacturing","Market (economics)","Market risk","Marketing","Matter","Mergers and acquisitions","Metaphysics","Microeconomics","Milestone","Money","Monopoly (economics)","Morality","National security","Natural resources law","Official documents","Open government","Opinion","Organization","Ownership","Patent","Payment","Payments","Percentage","Personal finance","Personality traits","Philosophy","Political economy","Political science","Politics","Politics of the United States","Price","Principles","Privacy","Private law","Professional ethics","Property","Property law","Psychological concepts","Psychology","Public administration","Public finance","Public law","Public policy","Public records","Public sector","Public sphere","Reason","Receipt","Redhill railway station","Redhill, Surrey","Regulation","Reimbursement","Research and development","Rights","Roman law","Rules","Science","Security","Semiotics","Separation of powers","Service industries","Services (economics)","Signature","Social institutions","Social issues","Social policy","Sociological theories","Sources","South African law","Split, Croatia","Statutory law","Steering","Tax","Tax credit","Taxation","Technology","Term sheet","Theories of law","Time","Truth","United States","United States dollar","United States economic policy","United States federal law","United States federal policy","United States law","United States legislation","Urban, rural, and regional economics","Value (economics)","Value (ethics)","Virtue","Warranty","World economy","Written communication"],"person_names":[],"vars":{"Party":{"IntelGenx Technologies Corp.":"[[Party 1]]"}},"organization_names":["igxt","intelgenx","redhill biopharma ltd.","sc","sec","vis a vis"],"agreement_id":"2148b0a3916623396081b846adbe7380784fab16e5f0375fa4c1cb3627074869","terms":["*   Primary responsibility for the development of the Product and the final vote on development, regulatory and manufacturing decisions *","*   Primary responsibility for the licensing and partnering of the Product and the final vote on partnering/licensing/commercialization decisions. *","*   Within 30 days of Closing: [****","*   Within 30 days of filing and acceptance of the NDA by the US FDA (“**","*   Within 30 days of successful completion of scale up, process development, and production of pivotal batches (“**","*   Within 30 days of the Product marketing approval (approval of the NDA of the Product) by the US FDA (“**","*   Within 60 days of Closing: [****","*   Within 7 days of Closing: [**","****","****] **","****] of Proceeds, RedHill shall receive [****","****] of any and all Proceeds exceeding [****","****]  [****","**ANNEX A**","**Annex B**","**CONFIDENTIAL TREATMENT REQUESTED**","**Collaboration Project**","**Confidentiality**","**Decision-making**","**Diligence Obligation**","**Diligence**","**Exclusivity and Due**","**Field**","**Governing Law**","**IP Ownership**","**In territories where RedHill sells the Product on its own:**","**In territories where the Product is marketed by a third party marketing**","**Limited Term**","**Payments**","**Proceeds**","**Product**","**R&D, Manufacturing**","**Redacted portions are indicated by [****","**Redacted portions filed separately with the SEC pursuant**","**Responsibilities and**","**Resulting**","**Rights in the Product**","**Steering Committee**","**Term Sheet: [****","**Territory**","**] and IGXT will receive [****","**and other Data**","**and**","**partner**","**to the confidential treatment request**","**“Diligence Obligation”)**","*actually received*","“**Agreement**”","“**Breakup Fee**”","“**Closing**”","“**Development Milestone I”**): [****]*   Within 30 days of filing and acceptance of the NDA by the US FDA (“**Development Milestone II”**): [****]*   Within 30 days of the Product marketing approval (approval of the NDA of the Product) by the US FDA (“**Development Milestone III”","“**Due Diligence Exclusivity Period**”","“**IGXT**”","“**Parties**”","“**Proceeds**”","“**Project**”","“**RedHill**”","“**SC**”","“**Term Sheet**”","”**). For the avoidance of any doubt, the Initial Proceeds Split will only apply once for the Product, and not per territory or per third party partner. Therefore, following the Initial Proceeds Split, RedHill will receive [****","”**): [****"]}}